APA

Trillet-Lenoir V., Chapuis F., Touzet S., Barbier J. Y., Freyer G., Gaudin J. L., Lombard-Bohas C., Valette P. J., Lledo G., Gouttebel M. C., Boyer J. D., Chassignol L., Hamon H., Claudel-Bonvoisin S., Leprince E., Amoyal P., Glehen O., Darnand P., Heilmann M. O. & Bleuse J. P. (20040824). Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?. : Clinical oncology (Royal College of Radiologists (Great Britain)).

Chicago

Trillet-Lenoir V, Chapuis F, Touzet S, Barbier J Y, Freyer G, Gaudin J L, Lombard-Bohas C, Valette P J, Lledo G, Gouttebel M C, Boyer J D, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glehen O, Darnand P, Heilmann M O and Bleuse J P. 20040824. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?. : Clinical oncology (Royal College of Radiologists (Great Britain)).

Harvard

Trillet-Lenoir V., Chapuis F., Touzet S., Barbier J. Y., Freyer G., Gaudin J. L., Lombard-Bohas C., Valette P. J., Lledo G., Gouttebel M. C., Boyer J. D., Chassignol L., Hamon H., Claudel-Bonvoisin S., Leprince E., Amoyal P., Glehen O., Darnand P., Heilmann M. O. and Bleuse J. P. (20040824). Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?. : Clinical oncology (Royal College of Radiologists (Great Britain)).

MLA

Trillet-Lenoir V, Chapuis F, Touzet S, Barbier J Y, Freyer G, Gaudin J L, Lombard-Bohas C, Valette P J, Lledo G, Gouttebel M C, Boyer J D, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glehen O, Darnand P, Heilmann M O and Bleuse J P. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?. : Clinical oncology (Royal College of Radiologists (Great Britain)). 20040824.